- Conditions
- Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- AZD4635, Oleclumab, Durvalumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Male only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 10,865
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Achondroplasia
- Interventions
- BMN 111
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 5 Years to 14 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 6
- States / cities
- Oakland, California • Torrance, California • Chicago, Illinois + 3 more
- Conditions
- Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
- Interventions
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo)
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 149
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 131 more
- Conditions
- Plaque Psoriasis
- Interventions
- Deucravacitinib, Ustekinumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 3,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 122
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 101 more
- Conditions
- Colon Cancer
- Interventions
- Topotecan
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Stroke, Intracranial Stenosis
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lip Augmentation
- Interventions
- Belotero® Intense Lidocaine, Restylane® Silk
- Device
- Lead sponsor
- Merz North America, Inc.
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 13
- States / cities
- Redondo Beach, California • Santa Monica, California • Vista, California + 9 more
- Conditions
- Select Advanced Solid Tumors
- Interventions
- IMCnyeso
- Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Iowa City, Iowa • St Louis, Missouri + 5 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-02341066
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,069 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 140
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 71 more
- Conditions
- Neonatal Abstinence Syndrome, Withdrawal
- Interventions
- Auricular acupuncture
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Up to 24 Hours
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Peripheral Blood Stem Cell Transplantation, Placebo Administration
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2027
- U.S. locations
- 140
- States / cities
- Scottsdale, Arizona • Duarte, California • Sacramento, California + 103 more
- Conditions
- Desmoid Tumor
- Interventions
- methotrexate, vinblastine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2006
- U.S. locations
- 36
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 28 more
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, cyclophosphamide, methotrexate
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Acute Pain
- Interventions
- Pharmacogenetic testing, Clinical decisions support
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 8 Years and older
- Enrollment
- 1,602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- Wilmington, Delaware • Gainesville, Florida • Jacksonville, Florida + 6 more
- Conditions
- Non-Alcoholic Steatohepatitis
- Interventions
- EDP-305 Dose 1, EDP-305 Dose 2, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 70
- States / cities
- Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 56 more
- Conditions
- Advanced Solid Tumor
- Interventions
- IMP1734
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 18 more
- Conditions
- High Risk Newly Diagnosed Multiple Myeloma
- Interventions
- Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant
- Drug
- Lead sponsor
- Multiple Myeloma Research Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 12
- States / cities
- Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- TAK-788, Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 11
- States / cities
- Long Beach, California • Orange, California • Palo Alto, California + 6 more
- Conditions
- Moderate to Severe Plaque-type Psoriasis
- Interventions
- Secukinumab (AIN457), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more
- Conditions
- Colorectal Cancer
- Interventions
- Simtuzumab, Placebo to match SIM, Leucovorin, Irinotecan, Fluorouracil
- Biological · Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 56
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Alhambra, California + 49 more
- Conditions
- Kidney Transplant, Chronic Kidney Disease
- Interventions
- Empagliflozin
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 19 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost (SR)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 38
- States / cities
- Sun City, Arizona • Huntington Beach, California • Irvine, California + 32 more
- Conditions
- Achondroplasia
- Interventions
- BMN 111
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 6
- States / cities
- Oakland, California • Torrance, California • Chicago, Illinois + 3 more
- Conditions
- Mucocutaneous Lymph Node Syndrome
- Interventions
- IVIG, Infliximab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more